Anti-PD-L1/PD-L2 therapeutic vaccination in untreated chronic lymphocytic leukemia patients with unmutated IgHV

Anti-PD-L1/PD-L2 therapeutic vaccination in untreated chronic lymphocytic leukemia patients with unmutated IgHV

Chronic lymphocytic leukemia (CLL) patients with unmutated immunoglobulin heavy chain (IgHV) are at risk of early disease progression compared to patients with mutated IgHV. As a preventive strategy, we treated 19 previously untreated CLL patients with unmutated IgHV in a phase 1/2 trial (clinicaltr...

Full description

Bibliographic Details
Main Authors: Uffe Klausen, Jacob Handlos Grauslund, Nicolai Grønne Dahlager Jørgensen, Shamaila Munir Ahmad, Merete Jonassen, Stine Emilie Weis-Banke, Evelina Martinenaite, Lone Bredo Pedersen, Thomas Landkildehus Lisle, Anne Ortved Gang, Lisbeth Enggaard, Morten Hansen, Morten Orebo Holmström, Özcan Met, Inge Marie Svane, Carsten Utoft Niemann, Lars Møller Pedersen, Mads Hald Andersen
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-11-01
Series:Frontiers in Oncology
Subjects:
PD-L1
PD-L2
chronic lymphocytic leukemia (CLL)
immunotherapy
cancer vaccine
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.1023015/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.1023015/full

Similar Items